WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Why Is Agenus Stock Gaining Monday? - Agenus (NASDAQ:AGEN)

Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.

Raccontata dabiopharmadive.commorningstar.combenzinga.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
benzinga.comStai leggendo2 g fa

Why Is Agenus Stock Gaining Monday? - Agenus (NASDAQ:AGEN)

Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.

originale
biopharmadive.com3 g fa

Agenus surges on study pivot; Apnimed lines up an IPO

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

Leggi questa versione → originale
morningstar.com3 g fa

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN…

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Leggi questa versione → originale

Timeline cronologica

  1. lunedì 13 luglio 2026·biopharmadive.com

    Agenus surges on study pivot; Apnimed lines up an IPO

    Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an…

  2. lunedì 13 luglio 2026·morningstar.com

    Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in…

    Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

  3. lunedì 13 luglio 2026·benzinga.com

    Why Is Agenus Stock Gaining Monday? - Agenus (NASDAQ:AGEN)

    Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.

  4. martedì 14 luglio 2026·benzinga.com

    Why Is Agenus Stock Falling on Tuesday? - Agenus (NASDAQ:AGEN)

    Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the latest clinical data and analyst updates.